Giant cell tumour of bone
- 1 July 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Oncology
- Vol. 21 (4), 338-344
- https://doi.org/10.1097/cco.0b013e32832c951d
Abstract
Giant cell tumour of bone (GCT) is the most common benign bone tumour and afflicts a young population. Treatment options for patients with unresectable disease have remained fairly static for the past three decades. Recent discoveries have identified a key role for the osteoclast differentiation factor, receptor activator of nuclear factor kappa B (NF-kappaB) ligand (RANKL), in the genesis of GCT. The development of the fully human monoclonal antibody to RANKL, denosumab, has led to a clinical trial in unresectable GCT. This study demonstrated an 86% response rate, with comparable evidence of clinical benefit, and was well tolerated. Other pathways that may present targets for therapy include the hypoxia-angiogenesis axis and the colony stimulating factor 1 receptor. Denosumab presents a new treatment option for patients with previously untreatable GCT. The eventual role of denosumab and other targeted agents in the treatment of GCT and related disorders is currently the subject of active study.Keywords
This publication has 48 references indexed in Scilit:
- Giant cell tumour of bone: morphological, biological and histogenetical aspectsInternational Orthopaedics, 2006
- Histologically verified lung metastases in benign giant cell tumours—14 cases from a single institutionInternational Orthopaedics, 2006
- Treatment of local recurrences of giant cell tumour in long bones after curettage and cementingThe Journal of Bone and Joint Surgery. British volume, 2006
- Osteoblast lineage properties in giant cell tumors of boneJournal of Orthopaedic Science, 2005
- The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysisCancer Treatment Reviews, 2004
- Hypoxia is a major stimulator of osteoclast formation and bone resorptionJournal of Cellular Physiology, 2003
- Phenol as an adjuvant for local control in the treatment ofgiant cell tumour of the boneEuropean Journal of Surgical Oncology, 1999
- Cryosurgery in the Treatment of Giant Cell TumorPublished by Ovid Technologies (Wolters Kluwer Health) ,1999
- Generalised giant-cell tumour of bone: Successful treatment of pulmonary metastases with interferon ?, a case reportZeitschrift für Krebsforschung und Klinische Onkologie, 1993
- Cytogenetic Analyses on Giant-Cell Tumors of BoneClinical Orthopaedics and Related Research, 1989